Results 71 to 80 of about 49,152 (197)

Report of Two Cases of Seronegative Rheumatoid Arthritis

مجله دانشکده پزشکی اصفهان, 2011
Background: About 10% of rheumatoid arthritis patients are seronegative, (rheumatoid factor is negative). These patients may be resistant to conventional anti-rheumatic drugs (DMARDs).
Mansour Salesi
doaj  

Serum Levels of Tartrate-Resistant Acid Phosphatase-5B in Breast Cancer Patients Treated with Pamidronate

The International Journal of Biological Markers, 2002
A novel immunoassay specific for the osteoclast-produced TRAP isoform 5b has been developed recently. By means of this assay we studied the usefulness of serum TRAP-5b in monitoring the response to palliative treatment with pamidronate in breast cancer ...
A. Martinetti, E. Seregni, C. Ripamonti, L. Ferrari, F. De Conno, R. Miceli, F. Pallotti, A. Coliva, D. Biancolini, E. Bombardieri   +9 more
doaj   +1 more source

Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group.

, 1998
PURPOSE To determine the efficacy and safety of 21 monthly cycles of pamidronate therapy in patients with advanced multiple myeloma. PATIENTS AND METHODS Patients with stage III myeloma and at least one lytic lesion received either placebo or pamidronate
A Lichtenstein, M Kovacs, M Heffernan, D J Reitsma, O Ballester, J R Berenson, J F Simeone, R D Knight, M A Dimopoulos, L Porter, H Blacklock, R Bordoni, A Keller, S George, J Seaman, R Bell, A Lipton   +16 more
core   +1 more source

Extraction socket healing in pediatric patients treated with intravenous pamidronate

, 2012
Background: Bisphosphonate use in adult patients has been linked to osteonecrosis of the jaw (ONJ). This complication has not been systematically assessed in a pediatric population receiving bisphosphonates.
Chahine, Carol Judith
core  

Primary prevention of glucocorticoid-induced osteoporosis with intermittent intravenous pamidronate: a randomized trial

, 1997
The aim of this study was to assess whether early intermittent I.V. administration of disodium pamidronate can effectively achieve primary prevention of glucocorticoid-induced osteoporosis (GIOP). A total of 27 in- or outpatients who required first-time,
Boutsen, Yves, Stoffel, M., Devogelaer, Jean-Pierre, Jamart, Jacques, Esselinckx, Walter   +4 more
core   +1 more source

Infusion rate and pharmacokinetics of intravenous pamidronate in the treatment of tumour-induced hypercalcaemia

, 1992
We report the results of two consecutive randomized studies in the treatment of malignant hypercalcaemia with intravenous pamidronate. Overall normocalcaemia was achieved in greater than 90% of patients and a single infusion of 60 mg pamidronate given ...
Dodwell, D J, Howell, A; id_orcid, Morton, A R, Daley-Yates, P T, Hoggarth, C R   +4 more
core   +4 more sources

Palliative pamidronate treatment in patients with bone metastases from breast cancer.

, 1993
PURPOSE An open, randomized study was performed to assess the effects of supportive pamidronate treatment on morbidity from bone metastases in breast cancer patients.
F J Cleton, G Blijham, S E Papapoulos, J P Neijt, L V Beex, J Hermans, H M Kroon, O L Bijvoet, H P Sleeboom, A T van Holten-Verzantvoort   +9 more
core   +1 more source

Use of pamidronate for osteoporosis treatment in public health care in Brazil

Revista Brasileira de Reumatologia
Purpose: The use of bisphosphonates for osteoporosis is effective in reducing the risk of fractures. However, oral formulations are sometimes not well tolerated or are contraindicated.
Leila Bianchet Zanatta, Cristina Marcatto, Cassio Slompo Ramos, Nadila Mañas, Carolina Moreira, Victoria Borba   +5 more
doaj   +1 more source

Effect of pamidronate and calcium on implant osseointegration in ovariectomized rats

Journal of Craniomaxillofacial Research, 2016
Introduction: Supplementation with minerals like calcium has been shown to be effective in preventing bone loss and increasing bone density. Thus, it can be assumed that if calcium supplementation is paired with bisphosphonates, greater benefit can be ...
Mehrnoush Momeni, Mahboube Hasheminasab, Moosa Mahmoodi, Mohammad Bayat   +3 more
doaj  

Hepatic Osteodystrophy: The Mechanism of Bone Loss in Hepatocellular Disease and the Effects of Pamidronate Treatment

Clinics
OBJECTIVES: The present study was designed to evaluate the bone phenotypes and mechanisms involved in bone disorders associated with hepatic osteodystrophy. Hepatocellular disease was induced by carbon tetrachloride (CCl4).
Adriano L. Spirlandeli, Ingrid Dick-de-Paula, Ariane Zamarioli, Vanda Jorgetti, Leandra N.Z. Ramalho, Marcello H. Nogueira-Barbosa, Jose B. Volpon, Alceu A. Jordão, Fernando Q. Cunha, Sandra Y. Fukada, Francisco J.A. de Paula   +10 more
doaj   +1 more source